Ather Energy Ltd. makes a corporate announcement

There is no single price for the Rs 1,200 Cr preferential issue:

• Rs 1,230 per equity share for the 16,26,016 shares issued to India-Japan Fund.
• Rs 1,260 per warrant, with each warrant convertible into one equity share, for Hero MotoCorp and the promoters. ^[1]

Implied valuation

Using the latest disclosed pre-issue share count of 383,120,970 shares as of May 30, 2026 ^[2], and adding the 16,26,016 equity shares plus 79,36,507 warrants ^[1]:

• Fully diluted post-issue shares: 392,683,493, or 39.268 Cr shares — derived.
• Weighted-average price across the equity shares and warrants: approximately Rs 1,254.90 — derived.
• Implied fully diluted post-money valuation: approximately Rs 49,278 Cr — derived.

Using only the warrant price of Rs 1,260 gives a valuation of approximately Rs 49,478 Cr; using the equity-share price of Rs 1,230 gives approximately Rs 48,300 Cr. The blended figure is the more appropriate representation because the fundraise has two different issue prices.

Comparison with DRHP-era funding valuations

A precise comparison with the previous funding rounds disclosed in the DRHP cannot be made from the cited DRHP excerpts because their round-by-round valuation figures are not separately reproduced. The available third-party reference places Ather’s last funding-round valuation at USD 1.30 billion as of August 13, 2024, according to PitchBook data ^[3]. Separately, a news summary describes the September 2024 DRHP as targeting an IPO valuation of USD 2.5 billion ^[4]. These are different benchmarks, and an INR/USD conversion rate is not specified.

Conclusion: the preferential issue implies a fully diluted valuation of roughly Rs 49,300 Cr, but a defensible percentage premium or discount versus the DRHP’s earlier funding-round valuations requires the actual DRHP valuation table and a consistent currency basis.

The Rs 2,500 Crores fundraise does not have a disclosed, itemized split between capital expenditure, working capital and R&D in the June 12 board resolution. It only approved an aggregate ceiling of Rs 1,500 Crores through QIP and a further Rs 1,000 Crores through equity shares, FCCBs or other convertible instruments ^{[5] [5]}.

The latest detailed object disclosure is for the Rs 1,200 Crores preferential issue, not the full Rs 2,500 Crores:

†Percentages are derived from the disclosed Rs 625 Crores, Rs 275 Crores and Rs 300 Crores allocations.

Implication: The documents do not earmark a specific amount from the overall Rs 2,500 Crores for Factory 3.0 or other capacity expansion, working capital, or R&D. Capacity expansion is a stated strategic requirement elsewhere, but the fundraise resolution does not assign a rupee amount to it. R&D is also not separately allocated in the latest preferential-issue objects. The only relevant bucket is the Rs 300 Crores general corporate-purpose allocation, which is broad enough to include working capital and additional capex, but its internal split is not disclosed ^[8].

On a full-receipt assumption, the Rs 2,500 Crores infusion would lift gross cash to approximately Rs 2,611.94 Crores from Rs 111.94 Crores. With Q4 FY26 total debt unchanged at Rs 513.07 Crores, pro-forma net cash would be approximately Rs 2,098.87 Crores. The mechanical runway rises substantially, but the reported cash-flow data does not support treating this as a clean 12–13 year operating runway.

Runway sensitivity

• Using Q1 FY27 net loss as a conservative burn proxy: Rs 51.09 Crores per quarter annualizes to Rs 204.36 Crores. Pro-forma gross cash would therefore cover approximately 12.8 years, versus roughly 0.55 years, or 6.6 months, on the pre-infusion cash balance. This is a mechanical derivation, not management guidance.
• Using reported operating cash flow: TTM operating cash flow was positive at Rs 31.89 Crores, so there is no finite operating-cash runway implied by the trailing figure. However, the positive number is small relative to the company’s expansion requirements and should not be interpreted as self-funding capacity.
• Including capex as a recurring cash requirement: If TTM capex of Rs 506.07 Crores continued and TTM operating cash flow remained at Rs 31.89 Crores, the implied annual funding requirement would be approximately Rs 474.18 Crores. On that broader cash-deployment basis, pro-forma cash covers roughly 5.5 years.

The key conclusion is that the infusion changes liquidity risk materially, but the practical runway will be determined by the pace of AURIC capacity expansion, product launches, working-capital investment and marketing. Management said the funds would support capacity expansion and faster product launches rather than remain idle cash ^[11]. Accordingly, 12.8 years is an accounting-loss scenario; around 5.5 years is a more conservative capex-inclusive reference point, before any acceleration in expansion spending.

There is also a basis caveat: the cash balance is standalone, while the latest Rs 51.09 Crores loss is consolidated, so the runway estimates are directional rather than fully like-for-like. The latest call also described the Rs 1,300 Crores QIP as closed while the additional Rs 1,200 Crores preference issue was still being completed ^[11]; therefore, Rs 2,611.94 Crores is a full-infusion pro-forma figure, not necessarily the cash balance immediately available at the latest reporting date.